Evolving landscape in the management of transthyretin amyloidosis

Annals of Medicine

Volumn 47, Issue 8, 2015, Pages 625-638

  Hawkins, Philip N ^a   Ando, Yukio ^b   Dispenzeri, Angela ^c   Gonzalez Duarte, Alejandra ^d   Adams, David ^e   Suhr, Ole B ^f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KUMAMOTO UNIVERSITY   (Japan)

^c MAYO CLINIC   (United States)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e BICÊTRE HOSPITAL   (France)

^f UMEÅ UNIVERSITY   (Sweden)

Author keywords

Amyloidosis; Cardiomyopathies; Polyneuropathies; RNA interference; Therapeutics; Transthyretin

Indexed keywords

1 [6 (2 CARBOXY 1 PYRROLIDINYL) 6 OXOHEXANOYL] 2 PYRROLIDINECARBOXYLIC ACID; 3,3 DIPHOSPHONO 1,2 PROPANODICARBOXYLIC ACID TC 99M; AMYLOID; AMYLOID PROTEIN; ANTISENSE OLIGONUCLEOTIDE; DIFLUNISAL; DOXYCYCLINE; GSK 2398852; ISIS TRANSTHYRETIN; PATISIRAN; PREALBUMIN; PYROPHOSPHATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; REVUSIRAN; TAFAMIDIS; TAUROURSODEOXYCHOLIC ACID; UNCLASSIFIED DRUG;

AMYLOIDOSIS; DISEASE ASSESSMENT; DISEASE COURSE; HUMAN; LIVER TRANSPLANTATION; MORBIDITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYNEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RNA INTERFERENCE; SCINTIGRAPHY; TRANSTHYRETIN AMYLOIDOSIS; AMYLOID NEUROPATHIES, FAMILIAL; ANIMAL; PHASE 3 CLINICAL TRIAL (TOPIC);

AMYLOID NEUROPATHIES, FAMILIAL; ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84948142085     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2015.1068949     Document Type: Review

References (136)

1. Ando Y, Coelho T, Berk L, Cruz W, Ericzon G, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013; 8: 31-8.
2. Monaco L, Rizzi M, Coda A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science. 1995; 268:1039-41.
3. Pepys B. Amyloidosis. Annu Rev Med. 2006;57:223-41.
4. Westermark P, Sletten K, Johansson B, Cornwell G. F ibril in sen ile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A. 1990; 87: 2843-5.
5. Benson D, Kincaid C. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36:411-23.
6. Coelho T, Maurer S, Suhr B. THAO S-The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyreting amy-loidosis. Curr Med Res Opin. 2013; 29: 63-76.
7. Sattianayagam T, Hahn F, Whelan J, Gibbs D, Pinney H, Stangou J, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33:1120-7.
8. Benson D, Teague D, Kovacs R, Feigenbaum H, Jung J, Kincaid C. Rate of progression of transthyretin amyloidosis. Am J Cardiol. 2011;108:285-9.
9. Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry. 2012;83:152-8.
10. Ruberg L, Maurer S, Judge P, Zeldenrust S, Skinner M, Kim Y, et al. Prospective evaluation of the morbidity and mortality of wild-type and Val122Ile mutant transthyretin amyloid cardiomyopa-thy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164:222-8.
11. Stewart M, Lenderking W, Lofus J, Murphy B, Alvir J, Shaffer S, et al. Evaluating the quality of life and burden of illness in an ultra-rare disease in the U.S.: transthyretin familial amyloid polyneuropathy (TTR-FAP) patients and caregivers. IXth International Symposium on Familial Amyloidotic Polyneuropathy (ISFAP), Rio de Janeiro, Brazil; 10-13 November 2013 [Poster No. E-16].
12. Stewart M, Lofus J, Lenderking W, Murphy B, Alvir J, Shaffer S, et al. Characterizing disease burden in an ultra-rare disease in the U.S.: transthyretin (TTR) amyloidosis patients and caregivers. ISPOR 16th Annual European Congress, Dublin, Ireland; 4-6 November 2013 [Poster No. PSY49].
13. Lachmann J, Gallimore R, Gillmore D, Carr-Smith D, Bradwell R, Pepys B, et al. O u tcom e in system ic A L am yloid osis in relation to changes in concentration of circulating free immu-noglobulin light chains following chemotherapy. Br J Haematol. 2003; 122: 78-84.
14. Adams D, Lozeron P, Lacroix C. A m ylo id n eu ro p ath ies. C u rr O p in Neurol. 2012; 25: 564-72.
15. Dohrn F, Rocken C, DeBleecker L, Martin J, Vorgerd M, VandenBergh Y, et al. Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol. 2013;260: 3093-108.
16. Planté-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology. 2007; 69: 693-8.
17. Hamour M, Lachmann J, Goodman J, Petrou M, Burke M, Hawkins N, et al. Heart transplantation for homozygous familial transthyretin (TTR) Val122Ile cardiac amyloidosis. Am J Transplant. 2008;8:1056-9.
18. Dharmarajan K, Maurer S. Transthyretin cardiac amyloidoses in older North Americans. J Am Geriatr Soc. 2012; 60: 765-74.
19. Ikeda S, Sekijima Y, Tojo K, Koyama J. D iagn ostic valu e of abd om in al wall fat pad biopsy in senile systemic amyloidosis. Amyloid. 2011;18:211-15.
20. van Gameren II, Hazenberg P, Bijzet J, vanRijswijk H. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. 2006; 54: 2015-21.
21. Do B, Coelho T, Sousa A, Guimaraes A. U sefu ln ess of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguese type. Amyloid. 2009;16:232-8.
22. Fine M, Arruda-Olson M, Dispenzieri A, Zeldenrust R, Gertz A, Kyle A, et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014;113:1723-7.
23. Adams D, Coelho T, Obici L, Merlini G, Mincheva Z, Suanprasert N, et al. Rapid progression of familial amyloid polyneuropathy: a multinational natural history study. Neurology. 2 015; 85:675-82.
24. Rosenzweig M, Landau H. Light chain (AL) amyloidosis: update on diagnosis and management. J Hematol Oncol. 2011;4:47-54.
25. Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P. Amyloidfibrilcompositionisrelatedtothephenotypeofhereditarytransthy-retinVal30Metamyloidosis.J Pathol. 2008; 216: 253-61.
26. Aljaroudi A, Desai Y, Tang H, Phelan D, Cerqueira D, Jaber A. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol. 2014;21:271-83.
27. Ihse E, Rapezzi C, Merlini G, Benson D, Ando Y, Suhr B, et al. Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid. 2013; 20: 142-50.
28. Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm T er. 2014; 39: 225-33.
29. Jacobson R, Pastore D, Yaghoubian R, Kane I, Gallo G, Buck S, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997; 336: 466-73.
30. Olsson M, Jonasson J, Cederquist K, Suhr B. F requ en cy of th e tran-sthyretin Val30Met mutation in the northern Swedish population. Amyloid. 2014;21:18-20.
31. Carvalho F, Sousa M, Fernandes S, Silva J, Saraiva J, Barros A. Preimplantation genetic diagnosis for familial amyloidotic polyneuropathy (FAP). Prenat Diagn. 2001;21:1093-9.
32. Morris M, Nicholes W, Benson M. P ren atal d iagn osis of h ered itary amyloidosis in a Portugese family. Am J Med Genet. 1991;39:123-4.
33. Hellman U, Alarcon F, Lundgren E, Suhr B, Bonaiti-PelliéC, Planté-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid. 2008;15:181-6.
34. Misu K, Hattori N, Nagamatsu M, Ikeda S, Ando Y, Nakazato M, et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain. 1999;122(Pt 10):1951-62.
35. Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011; 10: 1086-97.
36. Suhr O, Danielsson A, Holmgren G, Steen L. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med. 1994; 235: 479-85.
37. Rapezzi C, Merlini G, Quarta C, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: disease profi les and clinical courses of the 3 main types. Circulation. 2009;120:1203-12.
38. Lindqvist P, Olofsson O, Backman C, Suhr O, Waldenstrom A. Pulsed tissue Doppler and strain imaging discloses early signs of infi ltrative cardiac disease: a study on patients with familial amyloidotic polyneuropathy. Eur J Echocardiogr. 2006; 7: 22-30.
39. Dungu J, Sattianayagam T, Whelan J, Gibbs D, Pinney H, Banypersad M, et al. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J. 2012;164:72-9.
40. Fontana M, Banypersad M, Treibel A, Maestrini V, Sado M, White K, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014; 7: 157-65.
41. 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011;38:470-8.
42. Perugini E, Guidalotti L, Salvi F, Cooke M, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076-84.
43. Hutt F, Quigley M, Page J, Hall L, Burniston M, Gopaul D, et al. Utility and limitations of 3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014; 15: 1289-98.
44. 99m Tc-pyrophosphate scintigraphy for diff erentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013; 6: 195-201.
45. Kato-Motozaki Y, Ono K, Shima K, Morinaga A, Machiya T, Nozaki I, et al. Epidemiology of familial amyloid polyneuropathy in Japan: identification of a novel endemic focus. J Neurol Sci. 2008;270:133-40.
46. Ando Y, Nakamura M, Araki S Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005;62:1057-62.
47. Suanprasert N, Berk JL, Benson MD, Dyck PJ, Klein CJ, Gollob JA, et al. Retrospective study of a TTR FAP cohort to modify NIS + 7 for therapeutic trials. J Neurol Sci. 2014; 344: 121-8.
48. Riboldi G, Del Bo R, Ranieri M, Magri F, Sciacco M, Moggio M, et al. Tyr78Phe transthyretin mutation with predominant motor neuropathy as the initial presentation. Case Rep Neurol. 2011;3:62-8.
49. Hornsten R, Pennlert J, Wiklund U, Lindqvist P, Jensen SM, Suhr OB. Heart complications in familial transthyretin amyloidosis: impact of age and gender. Amyloid. 2010;17:63-8.
50. Koike H, Misu K, Ikeda S, Ando Y, Nakazato M, Ando E, et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early-vs late-onset form. Arch Neurol. 2002;59:1771-6.
51. Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner GG, Pinho e Costa P, Falcao de Freitas A, editors. Amyloid and amyloidosis. Amsterdam: Excerpta Medica; 1980. p. 88-93.
52. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, et al. Repurposing difl unisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013; 310: 2658-67.
53. Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Rodrigues Pena J, et al. Liver transplantation for hereditary transthyretin amyloidosis: af er 20 years still the best therapeutic alternative? Transplantation. 2 015;99:1847-54.
54. Ramalho A, Cortez-Dias N, Guimaraes T, Francisco AG, Nobre Menezes M, Lima Silva G, et al. Prognostic analysis of heart rate variability assessment in familial amyloid polyneuropathy. Eur Heart J. 2014; 35(Suppl): 933 [Abstract P5268].
55. Ramalho A, Cortez-Dias N, Lima Silva G, Placido R, Guimaraes T, Francisco AG, et al. Progression of cardiomyopathy in familial amyloid polyneuropathy-impacton prognosis.Eur Heart J.2014;35(Suppl.): 1058 [Abstract P5971].
56. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis aff ects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40:232-9.
57. Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, et al. Lef ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2:113-22.
58. Dharmarajan K, Salomon S, Helmke S, Tereyua S, Rapezzi C, Falk R, et al. Genotype and phenotypic characteristics of persons with cardiac amyloidosis from the Multinational Transthyretin Amyloidosis Survey (THAOS) registry. J Cardiac Fail. 2014; 117(Suppl): S69 [Abstract 221].
59. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126:1286-300.
60. Givens RC, Russo C, Green P, Maurer MS. Comparison of cardiac amyloidosis due to wild-type and Val122Ile transthyretin in older adults referred to an academic medical center. Aging Health. 2013; 9: 229-35.
61. Damy T, Jaccard A, Guellich A, Lavergne D, Rappeneau S, Deux JF, et al. Comparison and identifi cation of early clinical, biological and echocardiographic prognostic markers in transthyretin and AL cardiac amyloidosis. Eur Heart J. 2014; 35(Suppl): 668 [Abstract P3655].
62. Adams D. Recent advances in the treatment of familial amyloid polyneuropathy. Ter Adv Neurol Disord. 2013;6:129-39.
63. Algalarrondo V, Dinanian S, Juin C, Chemla D, Bennani SL, Sebag C, et al. Prophylactic pacemaker implantation in familial amyloid polyneuropathy. Heart Rhythm. 2012;9:1069-75.
64. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981;63:1285-8.
65. Gertz A, Falk H, Skinner M, Cohen S, Kyle A. W orsen in g of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol. 1985;55:1645.
66. Piccirillo G, Nocco M, Lionetti M, Moise A, Naso C, Marigliano V, et al. Eff ects of sildenafi l citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure. Am Heart J. 2002;143:703-10.
67. Adams D, Lozeron P, Teaudin M, Mincheva Z, Cauquil C, Adam C, et al. Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid. 2012;19(Suppl 1):61-4.
68. Adams D, Samuel D, Goulon-Goeau C, Nakazato M, Costa M, Feray C, et al. The course and prognostic factors of familial amyloid polyneuropathy afer liver transplantation. Brain. 2000;123(Pt 7): 1495-504.
69. Holmgren G, Steen L, Ekstedt J, Groth G, Ericzon G, Eriksson S, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet. 1991;40:242-6.
70. Suhr B, Ando Y, Holmgren G, Wikström L, Friman S, Herlenius G, et al. Liver transplantation in familial amyloidotic polyneuropathy (FAP). A comparative study of transplanted and non-transplanted patient's survival. Transpl Int. 1998;11(Suppl 1):S160-3.
71. Yamashita T, Ando Y, Okamoto S, Misumi Y, Hirahara T, Ueda M, et al. Long-term survival af er liver transplantation in patients with familial amyloid polyneuropathy. Neurology. 2012;78:637-43.
72. Yamamoto S, Wilczek E, Nowak G, Larsson M, Oksanen A, Iwata T, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant. 2007;7:2597-604.
73. Tsuchiya A, Yazaki M, Kametani F, Takei Y, Ikeda S. M arked regression of abdominal fat amyloid in patients with familial amyloid polyneu-ropathy during long-term follow-up af er liver transplantation. Liver Transpl. 2008;14:563-70.
74. Rydh A, Suhr O, Hietala O, Ahlstrom R, Pepys B, Hawkins N. Serum amyloid P component scintigraphy in familial amyloid polyneu-ropathy: regression of visceral amyloid following liver transplantation. Eur J Nucl Med. 1998;25:709-13.
75. Wilczek E, Larsson M, EriczonBG;FAPWTR.Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid. 2011;18(Suppl 1):193-5.
76. Herlenius G, Wilczek HE, Larsson M, Ericzon BG; Familial Amyloidotic Polyneuropathy World Transplant Registry. Ten years of international experience with liver transplantation for familial amy-loidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation. 2004; 77: 64-71.
77. Shimojima Y, Morita H, Kobayashi S, Takei Y, Ikeda S. Ten-year follow-up of peripheral nerve function in patients with familial amyloid polyneuropathy afer liver transplantation. J Neurol. 2008; 255:1220-5.
78. Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy afer liver transplantation. Neurology. 2010;75:324-7.
79. Ihse E, Suhr B, Hellman U, Westermark P. Variation in amount of wild-type transthyretin in diff erent fi bril and tissue types in ATTR amyloidosis. J Mol Med (Berl). 2011;89:171-80.
80. Olofsson O, Backman C, Karp K, Suhr B. Progressionofcardiomyopathyaferlivertransplantationinpatientswithfamilialamyloidoticpolyneuropathy, Portuguesetype.Transplantation. 2002; 73:745-51.
81. Yazaki M, Tokuda T, Nakamura A, Higashikata T, Koyama J, Higuchi K, et al. Cardiac amyloid in patients with familial amyloid polyneuropa-thy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun. 2000;274:702-6.
82. Stangou J, Hawkins N, Heaton D, Rela M, Monaghan M, Nihoyannopoulos P, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation. 1998;66:229-33.
83. Gustafsson S, Ihse E, Henein Y, Westermark P, Lindqvist P, Suhr B. Amyloid fi bril composition as a predictor of development of cardiomyopathy af er liver transplantation for hereditary transthyretin amyloidosis. Transplantation. 2012;93:1017-23.
84. Sekijima Y, Wiseman L, Matteson J, Hammarstrom P, Miller R, Sawkar R, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005;121:73-85.
85. SáCouto P, Barros F, Esteves S, Aragão I. Comparison of outcome data af er liver transplant: familial amyloid polyneuropathy (Portuguese type) recipients versus classical indications for liver transplant. Eur J Anaesthesiol. 2010;27:13 [Abstract 1AP3-6].
86. Barreiros P, Post F, Hoppe-Lotichius M, Linke P, Vahl F, Schafers J, et al. Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver Transpl. 2010;16:314-23.
87. Takei Y, Ikeda S, Ikegami T, Hashikura Y, Miyagawa S, Ando Y, et al. Ten years of experience with liver transplantation for familial amyloid polyneuropathy in Japan: outcomes of living donor liver transplantations. Intern Med. 2005;44:1151-6.
88. Bispo M, Marcelino P, Freire A, Martins A, Mourao L, Barroso E. High incidence of thrombotic complications early af er liver transplantation for familial amyloidotic polyneuropathy. Transpl Int. 2009; 22:165-71.
89. Nowak G, Suhr B, Wikstrom L, Wilczek H, Ericzon G. The longterm impact of liver transplantation on kidney function in familial amyloidotic polyneuropathy patients. Transpl Int. 2005;18:111-15.
90. Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg. 2002;236:429-36.
91. Rapezzi C, Perugini E, Salvi F, Grigioni F, Riva L, Cooke M, et al. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid. 2006;13:143-53.
92. Nelson M, Penninga L, Sander K, Hansen B, Villadsen E, Rasmussen A, et al. Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy. Clin Transplant. 2013;27:203-9.
93. Raichlin E, Daly C, Rosen B, McGregor G, Charlton R, Frantz P, et al. Combined heart and liver transplantation: a single-center experience. Transplantation. 2009;88:219-25.
94. Dubrey W, Burke M, Hawkins N, Banner R. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant. 2004; 23: 1142-53.
95. Rappley I, Monteiro C, Novais M, Baranczak A, Solis G, Wiseman L, et al. Quantification of transthyretin kinetic stability in human plasma using subunit exchange. Biochemistry. 2014; 53: 1993-2006.
96. Coelho T, Maia F, MartinsdaSilva A, Waddington M, Planté-Bordeneuve V, Lozeron P, et al. T afam id is for tran sth yretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012; 79: 785-92.
97. Merlini G, Planté-Bordeneuve V, Judge P, Schmidt H, Obici L, Perlini S, et al. E ff ects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013;6:1011-20.
98. Maurer S, Judge P, Rosas R, Mandel S, Aarts J. Interim analysis of long-term, open-label tafamidis treatment in transthyretin amyloid cardiomyopathy af er up to 5 years of treatment. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April-1 May 2014 [Presentation No. OP-66].
99. Lozeron P, Téaudin M, Mincheva Z, Ducot B, Lacroix C, Adams D, et al. Ef ect on disability and safety of tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2013; 20:1539-45.
100. Castaño A, Helmke S, Alvarez J, Delisle S, Maurer S. Difl unisal for ATTR cardiac amyloidosis. Congest Heart Fail. 2012;18:315-19.
101. Obici L, Cortese A, Lozza A, Palladini G, Perlini S, Gobbi M, et al. A phase II study of doxycycline plus tauroursodeoxycholic acid in transthyretin amyloidois. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April-1 May 2014 [Abstract OP-68].
102. Crooke T. ISIS Pharmaceuticals. J P Morgan Healthcare Conference. Available at: http://www.google.co.uk/url?sa=trct=j&q=&esrc=s&source=web&cd=3&cad=rja&uact=8&sqi=2&ved=0CD8QFjAC&url=http%3A%2F%2FError!Hyperlinkreferencenotvalid.JP%2520Morgan%2520Healthcare%2520%2520Presentation%25201-2013.pdf&ei=TLEqVIK5BoTB7gb87oCYCw&usg=AFQjCNFZE5NPGhbaAN8RwLwZ0K9kbziyZQ&bvm=bv.76477589 (accessed 16 January 2015).
103. Coelho T, Adams D, Silva A, Lozeron P, Hawkins N, Mant T, et al. Safety and effi cacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819-29.
104. Gollob J. Summary data from Phase II ALN-TTR02 RNAi treatment of ATTR. IXth International Symposium on Familial Amyloidotic Polyneuropathy (IFSAP). Rio de Janeiro, Brazil; 10-13 November 2013.
105. Coelho T, Suhr O, Conceicao I, Wadington-Cruz M, Schmidt H, Buades J, et al. Phase 2 open-label extension study of patisiran, an investigational RNAi therapeutic for the treatment of familial amyloid polyneuropathy. 67th Annual Meeting of the American Academy of Neurology (AAN), Washington, DC, USA; 18-25 April 2015 [Abstract S9.003].
106. Gillmore J, Falk R, Maurer M, Hanna M. Interim results from pilot phase 2 trial of revusiran (ALN-TTRsc). American Heart Association Annual Meeting Scientifi c Sessions. Chicago, IL, USA; 15-19 November 2014.
107. Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB, et al. Long-term ef ects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260: 2802-14.
108. Coelho T, Silva AM, Valdrez K, Cardoso M, Monteiro C, Ferreira H, et al. Familial amyloid polyneuropathy treatment with tafamidis-evaluation of one year treatment at Porto, Portugal. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April-1 May 2014 [Abstract OP-67].
109. Merlini G, Waddington CM, Stewart M, Rosas GR, Huertas PE, Man-del FS, et al. Survival in patients with transthyretin familial amyloid polyneuropathy receiving tafamidis treatment. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April-1 May 2014 [Abstract OP-65].
110. US Food and Drug Administration. Vyndaqel (tafamidis meglumine)-Proposed indication: treatment of transthyretin (TTR) familial amyloid polyneuropathy. Available at: http://www.fda.gov/downloads/AdvisorycommitteesMeetingMaterials/Drugs/PeripheralandCentral-NervousSystemDrugsAdvisoryCommittee/UCM304830.pdf (accessed 16 January 2015).
111. Rocha A, Silva AM, Cardoso M, Monteiro C, Beirão I, Alves C, et al. Treatment of ATTR Val30Met with tafamidis: successful decrease of proteinuria. XIVth International Symposium on Amyloidosis (ISA). Indianapolis, IN, USA; 27 April-1 May 2014.
112. National Amyloidosis Centre. ATTR Amyloidosis. Available at: http://www.amyloidosis.org.uk/introduction-to-attr-amyloidosis/(accessed 16 January 2015).
113. Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest. 2004;84:545-52.
114. Sekijima Y, Dendle MA, Kelly JW. Orally administered dif unisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006;13:236-49.
115. Sekijima Y, Tojo K, Morita H, Koyama J, Yazaki M, Ikeda S. Safety and effi cacy of long-term difl unisal administration in familial amyloid polyneuropathy-Summary of ten years therapeutic experience. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April-1 May 2014 [Abstract OP-70].
116. Hernández-Díaz S, Rodríguez A. Association between nonsteroidal anti-infl ammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160:2093-9.
117. Singh K, Haque E, Pillai K. Assessment of non steroid alanti-inflammatory drug-induced cardiotoxicity. Expert Opin Drug Metab Toxicol. 2014; 10: 143-56.
118. Reddy S, Roy A. Cardiovascular risk of NSAIDs: time to translate knowledge into practice. PLoS Med. 2013;10:e1001389.
119. Graham Y, Opekun R, Willingham F, Qureshi A. V isib le sm all-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55-9.
120. Quarta C, Falk H, Soloman D, Suhr B, Obici L, Perlini S, et al. The prevalence of cardiac amyloidosis in familial amyloidotic polyneuropathy with predominant neuropathy: The Diflunisal Trial. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April-1 May 2014 [Abstract OP-69].
121. Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva J. Synerg y of combined doxycycline/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010;8:74-84.
122. Gillmore D, Lovat B, Persey R, Pepys B, Hawkins N. Amyloid load and clinical outcome in amyloid A amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358:24-9.
123. Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. Haematologica. 2014; 99: 209-21.
124. Sanchorawala V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol. 2006; 1: 1331-41.
125. Benson D, Kluve-Beckerman B, Zeldenrust R, Siesky M, Bodenmiller M, Showalter D, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 2006; 33: 609-18.
126. Ackermann J, Guo S, Booten S, Benson M, Hughes S, Monia P. Clinical development of an antisense therapy for the treatment of hereditary transthyretin amyloidosis. XIIIth International Symposium on Amyloidosis (ISA), Groningen, Te Netherlands; 6-10 May 2012 [Abstract OP 73].
127. Butler S, Chan A, Costelha S, Fishman S, Milstein S, Willoughby S, et al. Preclinical evaluation of RNAi therapeutics for the treatment of ATTR: an update. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April-1 May 2014 [Abstract PC-9].
128. Suhr O, Adams D, Coelho T, Conceicao I, Waddington M, Schmidt H, et al. Further analysis of phase II trial of patisiran, a novel RNAi therapeutic for the treatment of familial amyloidotic polyneuropathy. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April-1 May 2014 [Abstract OP-72].
129. European Medicines Agency. Tafamidis EMA assessment report. Available at: http://www ema europa eu/docs/en-GB/document- library/EPAR-Public-assessment-report/human/002294/WC500117838 pdf (accessed 16 January 2015).
130. Zimmermann T, Karsten V, Harrop J, Chan A, Chiesa J, Peters G, et al. Phase I fi rst-in-human trial of ALN-TTRsc, a novel RNA interference therapeutic for the treatment of familial amyloidotic cardiomyopathy (FAC). Heart Failure Society of America 17th Annual Meeting; Orlando, FL, USA; 22-25 September 2013 [Poster].
131. Nair K, Willoughby L, Chan A, Charisse K, Alam R, Wang Q, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136:16958-61.
132. Obayashi K, Tasaki M, Jono H, Ueda M, Shinriki S, Misumi Y, et al. Impact of antibodies against amyloidogenic transthyretin (ATTR) on phenotypes of patients with familial amyloidotic polyneuropathy (FAP) ATTR Valine30Methionine. Clin Chim Acta. 2013;419:127-31.
133. Bodin K, Ellmerich S, Kahan C, Tennent A, Loesch A, Gilbertson A, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010;468:93-7.
134. Gillmore D, Tennent A, Hutchinson L, Gallimore R, Lachmann J, Goodman J, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol. 2010;148:760-7.
135. Planté-Bordeneuve V, Guendouz S, Damy T, Hulin A. Use of tafamidis in 3 transplanted amyloidosis ATTR-FAP patients: safety and association with immunosuppressive drugs. IXth Congress of Physiology, Pharmacology and Terapeutics, Poitiers, France; 22-24 April 2014 [Abstract PM1-043].
136. Yoshinaga T, Yazaki M, Sekijima Y, Kametani F, Ikeda S. Regression of gastroduodenal mucosal amyloid deposits in FAP patients af er combined therapy with oral intake of difl unisal followed by liver transplantation. XIVth International Symposium on Amyloidosis (ISA), Indianapolis, IN, USA; 27 April-1 May 2014 [Abstract OP-77].